DARE - Dare Bioscience, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.6600
+0.0400 (+2.47%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.6200
Open1.6500
Bid1.6300 x 3000
Ask1.6700 x 800
Day's Range1.6200 - 1.6800
52 Week Range0.6900 - 3.2500
Volume2,189,843
Avg. Volume1,480,545
Market Cap32.674M
Beta (5Y Monthly)1.50
PE Ratio (TTM)N/A
EPS (TTM)-1.0130
Earnings DateApr 01, 2020 - Apr 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
  • Analysts: 3 Healthcare Stocks That Could Gain 35% — Or More
    TipRanks

    Analysts: 3 Healthcare Stocks That Could Gain 35% — Or More

    Returns, that’s the name of the investing game. At the end of the day, investors are after the names that can help them generate a profit in the stock market. It’s as simple as that. The hard part, though, is determining which investment opportunities have the best chance of outperforming the market in the years to come.As not all stocks are created equal, Wall Street pros suggest doing some due diligence. This includes a close reading of what the analyst community has to say about the long-term growth prospects of a potential portfolio addition.Bearing this in mind, we applied this strategy to our own search for compelling investments in the healthcare space. With TipRanks’ Stock Screener tool, we used the sector, analyst consensus rating and price target upside filters to scan the market for the crème-de-la-crème. As a result, we pinpointed 3 buy-rated healthcare names that have received substantial support from Wall Street analysts. One more thing – each boasts over 30% upside potential from current levels. Let’s jump right in.GW Pharmaceuticals (GWPH) GW Pharmaceuticals leads the way when it comes to plant-derived cannabinoid therapeutics. It developed Epidiolex, the first cannabis plant-derived medicine to be approved by the FDA, which can be used for seizures associated with drug-resistant forms of epilepsy, Lennox-Gastaut Syndrome and Dravet Syndrome. While it has certainly struggled over the last six months, the Street is behind GWPH.On Monday, the company announced that Epidiolex revenue for the fourth quarter came in at $104 million, surpassing the $99 million consensus estimate. Not to mention this figure reflects an 18% quarter-over-quarter increase. While acknowledging that investors had expressed some doubts about the drug’s growth prospects, Cowen analyst Phil Nadeau argues that this performance should put these fears to bed.Adding to the good news, the five-star analyst believes that Epidiolex approval for tuberous sclerosis complex (TSC) is very likely. Importantly, this approval would expand its “penetration of the broader refractory epilepsy population.” As the CDC estimates there are 3.4 million people with active epilepsy in the U.S., with approximately one-third having seizures despite current regimens, the market opportunity is huge.An approval for TSC indication could also increase the average per patient dose of Epidiolex and allow for greater uptake among focal seizure patients. “These results may widen Epidiolex's dosing range by allowing physicians additional dosing flexibility for those patients who need it. The TSC data also establishes the efficacy of Epidiolex in focal seizures,” Nadeau noted.All of the above caused the analyst to conclude that the full value of the drug hasn’t been built into the share price. As a result, Nadeau reiterated an Outperform rating and $200 price target. Should the target be met, shares will be in for a 69% twelve-month gain. (To watch Nadeau’s track record, click here)What does the rest of the Street think? It turns out that they wholeheartedly agree with Nadeau. With 12 Buy ratings and no Holds or Sells, the message is clear: GWPH is a Strong Buy. If that wasn’t enough, the $200.70 average price target puts the upside potential at 69.5%. (See GW Pharmaceuticals stock analysis on TipRanks)Agios Pharmaceuticals (AGIO)Using its expertise in cellular metabolism and precision medicine, Agios Pharmaceuticals has developed a product pipeline to fight cancer and other rare genetic diseases. After it shared its vision for the company in the next five years, one analyst sees AGIO’s growth story as just getting started.Needham’s Chad Messer tells investors that management’s TIBSOVO guidance is encouraging. Expecting an increase in uptake for both the relapsed and frontline settings, the company predicts that full year 2020 sales could land within the range of $105 million to $115 million, an 80% year-over-year growth rate if achieved.With the drug currently being evaluated for further label expansion from frontline combinations in acute myeloid leukemia (AML) and approvals in myelodysplastic syndromes (MDS) and cholangiocarcinoma (CCA), the analyst thinks that TIBSOVO will be able to capture most AML patients with an IDH1 mutation in the next few years.Additionally, AGIO initiated two expansion cohorts in combination with taxanes in non-small-cell lung carcinoma (NSCLC) and pancreatic cancer in its third quarter and top-line data from both mitapivat pivotal studies should be released in 2020. “Mitapivat could be approved in adults with PKD by 2021, and in pediatric patients by 2024. Agios will also present data from the Phase II thalassemia study and provide details on a pivotal program in 2020. A Go/No-Go decision is expected for mitapivat in sickle cell anemia later this year. AG-946, a mitapivat follow-on, will enter the clinic in 2020,” Messer noted.Based on everything that the healthcare company has going for it, Messer decided to stay with the bulls, maintaining the Buy recommendation. The five-star analyst’s $71 price target implies upside potential of 35%. (To watch Messer’s track record, click here)Looking at the consensus breakdown, other analysts generally take a similar approach when it comes to AGIO. 8 Buys and 1 Hold assigned in the last three months add up to a Strong Buy consensus rating. A potential twelve-month climb of 24% could be in the cards given the $62.43 average price target. (See Agios stock analysis on TipRanks)Daré Bioscience (DARE)Following its 100% rise this week, the talk on Wall Street has shifted to Daré Bioscience. The massive gain came after the company, which develops novel therapies to improve the treatment options in women’s health, broke the news of its exclusive licensing agreement with Bayer for U.S. commercial rights to its non-hormonal, one-monthly vaginal contraceptive, Ovaprene.As part of the agreement, Daré will receive an undisclosed upfront payment, which could be up to $310 million in commercial milestones and tiered double-digit royalties. After a pivotal study is conducted, Bayer can obtain exclusive rights to commercialize Ovaprene in the U.S. If Bayer ultimately decides to make the $20 million opt-in, this will cause the exclusive license to go into effect.Maxim analyst Jason McCarthy argues that as Bayer will most likely make the $20 million payment, this deal reflects the large potential for Ovaprene. “Bayer sees the value in Ovaprene and is coming in now, with the license agreement, to be a part of the development process. This is the largest and possibly the only development stage deal in the category. We see this as validating for Ovaprene and Daré,” he explained.Given that Grand View Research estimates the contraceptive market could reach up to $11.6 billion by 2025, there is a significant opportunity. Noting that Bayer is already one of the largest players in the women’s health space, McCarthy stated, “The addition of Ovaprene is expected to expand the company’s contraceptive pipeline as the first and only non-hormonal vaginal ring product offered to women.”With this in mind, McCarthy left both his Buy rating and $3 price target as is. This conveys the analyst’s confidence in Daré’s ability to soar 94% over the next twelve months. (To watch McCarthy’s track record, click here)According to the consensus breakdown, McCarthy is the only analyst that has reviewed the stock in the last three months. To this end, the consensus rating is a Moderate Buy and the average price target matches that of McCarthy’s. However, given its impressive recent climb, more analyst ratings could be on the way.To find good ideas for healthcare stocks with solid upside potential, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • GlobeNewswire

    Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update

    SAN DIEGO, Jan. 15, 2020 -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast.

  • Business Wire

    Bayer and Daré Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene ®, an Investigational Hormone-Free, Monthly Contraceptive

    Bayer, a leader in women’s health, and Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health, announced today that the companies have signed a license agreement under which Bayer may commercialize Daré’s investigational contraceptive product, Ovaprene® in the United States once approved by the FDA.

  • GlobeNewswire

    Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study

    With the IND clearance from the FDA, Daré can commence the planned Phase 3 clinical study of DARE-BV1 in approximately 220 women in 2020 to support the New Drug Application (NDA) submission. Based on discussions with the FDA, the Phase 3 study will include a placebo control and assess the primary endpoint of clinical cure of BV (defined as resolution of specified clinical signs and symptoms from baseline visit) at the test-of-cure visit to occur 21 to 30 days after enrollment in the study, or the Day 21-30 visit.

  • GlobeNewswire

    Daré Bioscience Announces Alignment with the FDA on Phase 2b Study Design and Novel Primary Endpoint PRO Instruments to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the outcome of a Type C meeting with the U.S. Food and Drug Administration (FDA) where alignment was reached on the patient reported outcome (PRO) instruments to be used in a Phase 2b clinical study of Sildenafil Cream, 3.6% (Sildenafil Cream) to screen eligible patients with Female Sexual Arousal Disorder (FSAD) and to assess the efficacy of Sildenafil Cream in treating FSAD. The discussions with the FDA followed the completion of a content validity study of the proposed PRO instruments, a non-interventional study integral to initiating the at-home, product dosing portion of the Sildenafil Cream Phase 2b program.

  • GlobeNewswire

    Daré Bioscience Announces Feature Presentation at the15th US-Japan Symposium on Drug Delivery Systems

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that it will give one of the feature presentations at the 15th US-Japan Symposium on Drug Delivery Systems taking place Saturday, December 14 through Wednesday, December 18, 2019 in Maui, Hawaii. The presentation entitled, “Personalizing drug delivery for women: A vaginal ring to rule them all” will be presented by Sabrina Martucci Johnson, President and CEO of Daré Bioscience. Daré’s novel intravaginal ring (IVR) technology was developed by Dr. Robert Langer from the Massachusetts Institute of Technology and Dr. William Crowley from Massachusetts General Hospital and Harvard Medical School.

  • DARE: Our Take On Ovaprene PCT Data, BV-1 Pivotal Study Design and Microchips Acquisition
    Zacks Small Cap Research

    DARE: Our Take On Ovaprene PCT Data, BV-1 Pivotal Study Design and Microchips Acquisition

    By Brian Marckx, CFA NASDAQ:DARE | NYSE:AGN READ THE FULL DARE RESEARCH REPORT Q3 2019 Pipeline and Financials Update Daré Bioscience, Inc (NASDAQ:DARE) has been extremely busy lately as their acquisition strategy continues in parallel with their organic product and pipeline development. They continue to make seemingly unimpeded progress on almost all of their top development programs and could

  • Thomson Reuters StreetEvents

    Edited Transcript of DARE earnings conference call or presentation 14-Nov-19 9:30pm GMT

    Q3 2019 Dare Bioscience Inc Earnings Call

  • GlobeNewswire

    Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform

    Daré Bioscience, Inc. (NASDAQ:DARÉ), a leader in women’s health innovation, today announced the closing of the previously announced acquisition by merger of privately-held Microchips Biotech, Inc.  As a result of the transaction, Microchips is a wholly owned subsidiary of Daré. Microchips is developing an innovative, wireless, user-controlled drug delivery technology with potential utility across multiple therapeutic areas, including contraception. The application of this technology in developing a contraceptive product has been supported by the Gates Foundation in the form of approximately $17.9 million in grant funding to date.

  • Benzinga

    The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 13.) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals ...

  • GlobeNewswire

    Daré Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2019 and provided a company update. “The third quarter was marked by tremendous progress for Daré and positioned us to reach a number of milestones in the fourth quarter of 2019 and into 2020,” said Sabrina Martucci Johnson, President and CEO of Daré. “In the third quarter, we also advanced our DARE-BV1 and Sildenafil Cream, 3.6% programs,” continued Ms. Johnson.

  • GlobeNewswire

    Daré Bioscience Announces Positive Findings from a Postcoital Test Clinical Study of Ovaprene® Hormone-Free Contraceptive Candidate

    Across all women and all cycles evaluated, Ovaprene prevented essentially all sperm from entering the cervical canal, a surrogate marker for contraceptive effectiveness. Currently marketed contraceptives with similar results in their PCT clinical studies subsequently demonstrated 6-month “typical use” effectiveness of 86-91% in their pivotal clinical trials, in the same range as traditional hormonal contraceptive methods. SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced positive topline results from the Ovaprene postcoital test (PCT) clinical study, a multi-center, open-label, non-significant risk device pre-pivotal trial.

  • GlobeNewswire

    Daré Bioscience Enters into Agreement to Acquire Microchips Biotech Including Its First-in-Class Wireless, User-Controlled Drug Delivery Platform

    Daré Bioscience, Inc. (NASDAQ:DARÉ), a leader in women’s health innovation, today announced it entered into an agreement to acquire privately-held Microchips Biotech, Inc.  Daré entered into the agreement to secure Microchips’ innovative, drug delivery technology. “The addition of this user-controlled, long-acting reversible contraceptive opportunity to Daré’s pipeline, which already includes the novel monthly, hormone-free contraceptive Ovaprene, will uniquely position Daré with two of the potentially most disruptive innovations in the contraceptive category.

  • GlobeNewswire

    Daré Bioscience to Host Third Quarter 2019 Financial Results and Company Update Conference Call and Webcast

    SAN DIEGO, Nov. 07, 2019 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast.

  • GlobeNewswire

    Daré Bioscience Announces Presentation of Two Posters at American Association of Pharmaceutical Scientists 2019 PharmSci 360

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that it will be presenting findings from two nonclinical studies at the upcoming American Association of Pharmaceutical Scientists 2019 PharmSci 360 conference taking place in San Antonio, Texas at the Henry B. Gonzalez Convention Center, November 3–6, 2019. The two posters, entitled, “Vaginal Tamoxifen for Treatment of Vulvovaginal Atrophy: Pharmacokinetics and Safety in a Rabbit Model” and “Evaluation of Different Suppliers of Ethylene Vinyl Acetate Used in Intravaginal Rings,” will be presented by David Friend, PhD, Chief Scientific Officer of Daré Bioscience.

  • GlobeNewswire

    Daré Bioscience and Strategic Science & Technologies Announce Presentation of Positive Findings from Thermography Clinical Study of Sildenafil Cream, 3.6 % in Healthy Women at the Sexual Medicine Society of North America Conference

    Sildenafil Cream, 3.6% produced statistically significant and clinically meaningful responses compared to placebo cream, further validating the potential for Sildenafil Cream, 3.6% to be an on-demand treatment for FSAD. SAN DIEGO, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced a poster presentation at the Sexual Medicine Society of North America 20th Annual Fall Scientific Meeting, which took place in Nashville, Tennessee, October 24-27, 2019. Daré, in collaboration with SST, is developing Sildenafil Cream, 3.6% as a potential treatment for female sexual arousal disorder (FSAD).

  • Companies Like Daré Bioscience (NASDAQ:DARE) Can Be Considered Quite Risky
    Simply Wall St.

    Companies Like Daré Bioscience (NASDAQ:DARE) Can Be Considered Quite Risky

    Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

  • GlobeNewswire

    Daré Bioscience to Participate in Two Upcoming Investor Conferences

    SAN DIEGO, Oct. 14, 2019 -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, its President and Chief Executive.

  • GlobeNewswire

    Daré Bioscience Announces a Poster Presentation on a Pharmacokinetic Study of DARE-FRT1, in Development for Sustained-Release Progesterone Therapy for Pregnancy Maintenance, at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced a poster presentation at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress & Expo, which will take place in Philadelphia, Pennsylvania, October 12-16, 2019. Daré’s Chief Scientific Officer, David Friend, PhD, will present findings from a pharmacokinetic animal study of DARE-FRT1, which is being developed for the prevention of preterm birth and as a new option for luteal phase support following in-vitro fertilization (IVF). DARE-FRT1 is part of Daré’s novel intravaginal ring (IVR) technology platform and is designed to allow for convenient non-invasive, non-oral administration of bio-identical progesterone during a 14-day period.

  • GlobeNewswire

    Daré Bioscience to Present an Overview on its Intravaginal Ring (IVR) Technology in Development for Sustained-Release Hormone Therapy and Pregnancy Maintenance at the 9th Annual Partnership Opportunities in Drug Delivery Conference

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that David Friend, Ph.D., its Chief Scientific Officer, will present at the 9th annual Partnership Opportunities in Drug Delivery conference being held October 7-8, 2019 in Boston, MA. “Our segmented IVR technology is designed to provide a convenient approach for sustained drug delivery of one or more drugs at variable dosages for up to four weeks,” said Dr. Friend.

  • Thomson Reuters StreetEvents

    Edited Transcript of DARE earnings conference call or presentation 14-Aug-19 8:30pm GMT

    Q2 2019 Dare Bioscience Inc Earnings Call

  • GlobeNewswire

    Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Pharmaceutics

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced the article entitled “Vaginal tamoxifen for treatment of vulvar and vaginal atrophy: Pharmacokinetics and local tolerance in a rabbit model over 28 days” was published online in the International Journal of Pharmaceutics. The article highlights the positive findings from the animal study which include availability and local tolerability of vaginally delivered tamoxifen. DARE-VVA1 is a novel vaginal application of tamoxifen, the well-known and well-characterized selective estrogen receptor modulator (SERM), and is being developed by Daré as an alternative to estrogen-based therapies for the treatment of vulvar and vaginal atrophy (VVA) in women with or at risk for hormone-receptor positive (HR+) breast cancer.

  • Could The Daré Bioscience, Inc. (NASDAQ:DARE) Ownership Structure Tell Us Something Useful?
    Simply Wall St.

    Could The Daré Bioscience, Inc. (NASDAQ:DARE) Ownership Structure Tell Us Something Useful?

    If you want to know who really controls Daré Bioscience, Inc. (NASDAQ:DARE), then you'll have to look at the makeup of...

  • GlobeNewswire

    Daré Bioscience Announces Completion of its Content Validity Study to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the completion of a content validity study, a non-interventional study integral to initiating the at-home, product dosing portion of the Sildenafil Cream, 3.6% (Sildenafil Cream) Phase 2b program. Daré plans to review the findings of the content validity study with the U.S. Food and Drug Administration (FDA) in a Type C meeting and to seek alignment on the patient reported outcome (PRO) instruments to be used to screen eligible patients with Female Sexual Arousal Disorder (FSAD) and to assess the efficacy of Sildenafil Cream in treating FSAD.